179 related articles for article (PubMed ID: 35412039)
21. Differential diagnosis of smooth muscle tumors utilizing p53, pTEN and Ki-67 expression with estrogen and progesterone receptors.
Gökaslan H; Türkeri L; Kavak ZN; Eren F; Sişmanoğlu A; Ilvan S; Durmuşoğlu F
Gynecol Obstet Invest; 2005; 59(1):36-40. PubMed ID: 15377824
[TBL] [Abstract][Full Text] [Related]
22. Fascin expression in uterine smooth muscle tumors.
Kefeli M; Yildiz L; Kaya FC; Aydin O; Kandemir B
Int J Gynecol Pathol; 2009 Jul; 28(4):328-33. PubMed ID: 19483633
[TBL] [Abstract][Full Text] [Related]
23. Epithelioid smooth muscle tumors of the uterus do not express CD1a: a potential immunohistochemical adjunct in their distinction from uterine perivascular epithelioid cell tumors.
Fadare O; Liang SX
Ann Diagn Pathol; 2008 Dec; 12(6):401-5. PubMed ID: 18995203
[TBL] [Abstract][Full Text] [Related]
24. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis.
Bodner-Adler B; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
Gynecol Oncol; 2005 Jan; 96(1):62-6. PubMed ID: 15589581
[TBL] [Abstract][Full Text] [Related]
25. Uterine smooth muscle tumors of uncertain malignant potential (STUMP): a clinicopathologic analysis of 16 cases.
Ip PP; Cheung AN; Clement PB
Am J Surg Pathol; 2009 Jul; 33(7):992-1005. PubMed ID: 19417585
[TBL] [Abstract][Full Text] [Related]
26. The Clinicopathological Study of 21 Cases With Uterine Smooth Muscle Tumors of Uncertain Malignant Potential: Centralized Review Can Purify the Diagnosis.
Basaran D; Usubutun A; Salman MC; Narin MA; Boyraz G; Turkmen O; Comert Kimyon G; Karalok A; Bulbul D; Turan T; Ozgul N; Yuce K
Int J Gynecol Cancer; 2018 Feb; 28(2):233-240. PubMed ID: 29303932
[TBL] [Abstract][Full Text] [Related]
27. Expression of Ki-67, P53 and progesterone receptors in uterine smooth muscle tumors. Diagnostic value.
Petrović D; Babić D; Forko JI; Martinac I
Coll Antropol; 2010 Mar; 34(1):93-7. PubMed ID: 20437637
[TBL] [Abstract][Full Text] [Related]
28. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors.
Mittal K; Demopoulos RI
Hum Pathol; 2001 Sep; 32(9):984-7. PubMed ID: 11567229
[TBL] [Abstract][Full Text] [Related]
29. EMMPRIN (CD147) Expression in Smooth Muscle Tumors of the Uterus.
Kefeli M; Yildiz L; Gun S; Ozen FZ; Karagoz F
Int J Gynecol Pathol; 2016 Jan; 35(1):1-7. PubMed ID: 26352545
[TBL] [Abstract][Full Text] [Related]
30. An immunohistochemical analysis of stathmin 1 expression in uterine smooth muscle tumors: differential expression in leiomyosarcomas and leiomyomas.
Allen MM; Douds JJ; Liang SX; Desouki MM; Parkash V; Fadare O
Int J Clin Exp Pathol; 2015; 8(3):2795-801. PubMed ID: 26045786
[TBL] [Abstract][Full Text] [Related]
31. Practical issues in uterine pathology from banal to bewildering: the remarkable spectrum of smooth muscle neoplasia.
Oliva E
Mod Pathol; 2016 Jan; 29 Suppl 1():S104-20. PubMed ID: 26715170
[TBL] [Abstract][Full Text] [Related]
32. [Mesenchymal uterine tumors. Leiomyomas].
Lax S
Pathologe; 2009 Jul; 30(4):274-83. PubMed ID: 19495761
[TBL] [Abstract][Full Text] [Related]
33. Molecular analyses of 6 different types of uterine smooth muscle tumors: Emphasis in atypical leiomyoma.
Zhang Q; Ubago J; Li L; Guo H; Liu Y; Qiang W; Kim JJ; Kong B; Wei JJ
Cancer; 2014 Oct; 120(20):3165-77. PubMed ID: 24986214
[TBL] [Abstract][Full Text] [Related]
34. Differential expression of P16 and P21 in benign and malignant uterine smooth muscle tumors.
Ünver NU; Acikalin MF; Öner Ü; Ciftci E; Ozalp SS; Colak E
Arch Gynecol Obstet; 2011 Aug; 284(2):483-90. PubMed ID: 20878171
[TBL] [Abstract][Full Text] [Related]
35. The Usefulness of Immunohistochemistry in the Differential Diagnosis of Lesions Originating from the Myometrium.
Rubisz P; Ciebiera M; Hirnle L; Zgliczyńska M; Łoziński T; Dzięgiel P; Kobierzycki C
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30845657
[TBL] [Abstract][Full Text] [Related]
36. PD-L1 Expression and Tumor-infiltrating Lymphocytes in Uterine Smooth Muscle Tumors: Implications for Immunotherapy.
Shanes ED; Friedman LA; Mills AM
Am J Surg Pathol; 2019 Jun; 43(6):792-801. PubMed ID: 31009388
[TBL] [Abstract][Full Text] [Related]
37. Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors.
Croce S; Ducoulombier A; Ribeiro A; Lesluyes T; Noel JC; Amant F; Guillou L; Stoeckle E; Devouassoux-Shisheboran M; Penel N; Floquet A; Arnould L; Guyon F; Mishellany F; Chakiba C; Cuppens T; Zikan M; Leroux A; Frouin E; Farre I; Genestie C; Valo I; MacGrogan G; Chibon F
Mod Pathol; 2018 May; 31(5):816-828. PubMed ID: 29327710
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic value of progesterone receptor and p53 expression in uterine smooth muscle tumors.
Hewedi IH; Radwan NA; Shash LS
Diagn Pathol; 2012 Jan; 7():1. PubMed ID: 22217299
[TBL] [Abstract][Full Text] [Related]
39. Atypical Uterine Smooth Muscle Tumors: A Retrospective Evaluation of Clinical and Pathologic Features.
Maltese G; Fontanella C; Lepori S; Scaffa C; Fucà G; Bogani G; Provenzano S; Carcangiu ML; Raspagliesi F; Lorusso D
Oncology; 2018; 94(1):1-6. PubMed ID: 28869928
[TBL] [Abstract][Full Text] [Related]
40. Uterine perivascular epithelioid cell tumors (PEComas) and epithelioid smooth muscle neoplasms.
Fadare O
Arch Pathol Lab Med; 2008 Nov; 132(11):1714. PubMed ID: 18976002
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
